Recombinant factor VIII may not abolish risk of new variant CJD from factor VIIIBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7141.1385 (Published 02 May 1998) Cite this as: BMJ 1998;316:1385
- J P Betts, International technical affairs director
- Grupo Grifols, Cambridge CB4 4GP
EDITOR—Barbara and Flanagan report the precautionary measures against new variant Creutzfeldt-Jakob disease that have been announced by the UK Department of Health.1 Unfortunately, the secretary of state announced the outcome of the NHS review of the provision of factor VIII for patients with haemophilia at the same time. The rationale for endorsing the use of recombinant factor VIII in children has thus become linked to concerns over new variant Creutzfeldt-Jakob.
Recombinant factor VIII is a biologically derived product produced by cell culture, not a synthetic product as stated in the announcement …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial